Veracyte Contemplated Oper Expenses of Convergent in 2026 Adj EBITDA Guidance and Isn't Updating at This Time >VCYT
Veracyte Contemplated Oper Expenses of Convergent in 2026 Adj EBITDA Guidance and Isn't Updating at This Time >VCYT
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Veracyte Acquires Convergent Genomics In $150M Deal, With Up To $30M Milestone Payments
Veracyte, Inc. (NASDAQ: VCYT ), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically va